JP2006518756A - インドリノン化合物による過度の骨溶解の治療 - Google Patents

インドリノン化合物による過度の骨溶解の治療 Download PDF

Info

Publication number
JP2006518756A
JP2006518756A JP2006503797A JP2006503797A JP2006518756A JP 2006518756 A JP2006518756 A JP 2006518756A JP 2006503797 A JP2006503797 A JP 2006503797A JP 2006503797 A JP2006503797 A JP 2006503797A JP 2006518756 A JP2006518756 A JP 2006518756A
Authority
JP
Japan
Prior art keywords
group
alkyl
heteroaryl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006503797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518756A5 (enExample
Inventor
ムレー，レズレイ
オファレル，アン・マリー
アブラムス，ティンヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of JP2006518756A publication Critical patent/JP2006518756A/ja
Publication of JP2006518756A5 publication Critical patent/JP2006518756A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006503797A 2003-02-24 2004-02-23 インドリノン化合物による過度の骨溶解の治療 Withdrawn JP2006518756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44886103P 2003-02-24 2003-02-24
US10/780,917 US20040209937A1 (en) 2003-02-24 2004-02-19 Treatment of excessive osteolysis with indolinone compounds
PCT/US2004/005283 WO2004075775A2 (en) 2003-02-24 2004-02-23 Treatment of excessive osteolyisis with indolinone compounds

Publications (2)

Publication Number Publication Date
JP2006518756A true JP2006518756A (ja) 2006-08-17
JP2006518756A5 JP2006518756A5 (enExample) 2007-02-15

Family

ID=32930497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503797A Withdrawn JP2006518756A (ja) 2003-02-24 2004-02-23 インドリノン化合物による過度の骨溶解の治療

Country Status (11)

Country Link
US (1) US20040209937A1 (enExample)
EP (1) EP1599207A2 (enExample)
JP (1) JP2006518756A (enExample)
KR (1) KR20050113612A (enExample)
AU (1) AU2004216188A1 (enExample)
BR (1) BRPI0407793A (enExample)
CA (1) CA2516786A1 (enExample)
MX (1) MXPA05008961A (enExample)
NZ (1) NZ541825A (enExample)
PL (1) PL378762A1 (enExample)
WO (1) WO2004075775A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526615A (ja) * 2008-07-02 2011-10-13 ジェネリクス・（ユーケー）・リミテッド ３−ピロール置換２−インドリノン誘導体の調製
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・（ユーケー）・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
JP2012506893A (ja) * 2008-10-28 2012-03-22 レツク・フアーマシユーテイカルズ・デー・デー スニチニブの新規な塩
JP2012508719A (ja) * 2008-11-13 2012-04-12 レツク・フアーマシユーテイカルズ・デー・デー スニチニブマレートの新たな結晶形

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
WO2007034272A1 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Solid salt forms of a pyrrole substituted 2-indolinone
EP1977238B1 (en) * 2005-12-22 2016-09-28 Novartis AG Soluble human m-csf receptor and uses thereof
CN101367801B (zh) 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
WO2010011834A2 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CN102239163A (zh) * 2008-07-24 2011-11-09 特瓦制药工业有限公司 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US10898211B2 (en) 2015-01-14 2021-01-26 Crossroads Extremity Systems, Llc Opening and closing wedge osteotomy guide and method
US10292713B2 (en) 2015-01-28 2019-05-21 First Ray, LLC Freeform tri-planar osteotomy guide and method
US10376268B2 (en) 2015-02-19 2019-08-13 First Ray, LLC Indexed tri-planar osteotomy guide and method
EP3470394B1 (en) * 2016-06-09 2022-01-26 Yuki Gosei Kogyo Co., Ltd. Method for preparing 4-(piperidin-4-yl)morpholine
CN114513994B (zh) 2019-07-26 2025-08-01 汇聚义肢系统有限责任公司 骨复位引导系统和方法
US11779359B2 (en) 2020-02-19 2023-10-10 Crossroads Extremity Systems, Llc Systems and methods for Lapidus repair of bunions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1255752E (pt) * 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
EP1434774A1 (en) * 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
US20040018528A1 (en) * 2002-05-17 2004-01-29 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526615A (ja) * 2008-07-02 2011-10-13 ジェネリクス・（ユーケー）・リミテッド ３−ピロール置換２−インドリノン誘導体の調製
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・（ユーケー）・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
JP2012506893A (ja) * 2008-10-28 2012-03-22 レツク・フアーマシユーテイカルズ・デー・デー スニチニブの新規な塩
JP2012508719A (ja) * 2008-11-13 2012-04-12 レツク・フアーマシユーテイカルズ・デー・デー スニチニブマレートの新たな結晶形

Also Published As

Publication number Publication date
BRPI0407793A (pt) 2006-02-14
PL378762A1 (pl) 2006-05-15
AU2004216188A1 (en) 2004-09-10
US20040209937A1 (en) 2004-10-21
NZ541825A (en) 2008-11-28
MXPA05008961A (es) 2005-11-04
WO2004075775A2 (en) 2004-09-10
KR20050113612A (ko) 2005-12-02
EP1599207A2 (en) 2005-11-30
WO2004075775A3 (en) 2005-04-14
CA2516786A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
NL1024779C2 (nl) Gecombineerde toediening van een indolinon met een chemotherapeutisch middel voor celproliferatiestoornissen.
AU2002360314B2 (en) Treatment of acute myeloid leukemia with indolinone compounds
JP2006518756A (ja) インドリノン化合物による過度の骨溶解の治療
JP3677501B2 (ja) 蛋白質キナーゼ阻害剤としての３−（４−アミドピロール−２−イルメチリデン）−２−インドリノン誘導体
CN102271681B (zh) Cxcr7调节剂
AU2002360314A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
JP2003534341A (ja) ３−（ピロール−２−イルメチリデン）−２−インドリノン誘導体のプロドラッグ
EA005996B1 (ru) Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
JP2023541522A (ja) 低分子量タンパク質分解物質及びその適用
JP2003535038A (ja) 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
WO2022233782A1 (en) Composition comprising an inhibitor of mitochondrial transcription
ES2374570T3 (es) Tratamiento de tumores metastalizados.
TWI699366B (zh) 治療或預防癌症的化合物
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061219

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081118

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090105